CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ULISES project is developing an immunotherapy that reprograms cancer cells to be recognized and attacked by the body's immune system. Using nanoparticles to deliver genetic material, this approach aims to treat pancreatic cancer and potentially other cancers with minimal side effects.
In the ULISES project, we aim at developing an immunologic-based treatment strategy where cancer cells are “reprogrammed” to become “visible” to the patient’s own immune system, which will see them as “not belonging to the body” and will attack them, emulating the allogenic response to incompatible transplants.
Thus, it will constitute a “natural” treatment, as the patient’s own immune system will be used to attack cancer cells, with no drugs, chemotherapy, radiotherapy, transplants, etc., signi…
FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Spain
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Utrecht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
